Associate Director, MGB Laboratory of Molecular Medicine
Director, Translational Genomics Core, MGB Personalized Medicine
Assistant Professor of Pathology Harvard Medical School
Dr. Sami S Amr is an Assistant Professor in the
Department of Pathology at Brigham and Women’s Hospital and Harvard Medical
School. He is also Associate Director of the Laboratory of Molecular Medicine
and Director of the Biobank Genomics Core at Mass General Brigham Personalized
Medicine. Dr. Amr is also board certified in clinical molecular genetics by the
American Board of Medical Genetics and Genomics (ABMGG).
Dr. Amr’s career spans over 10 years in clinical molecular diagnostics, where he has led the development and implementation of several clinical assays including large gene panels for inherited disease as well as smaller panels/assays for technically challenging regions or genes. In addition, has been involved in analysis, interpretation and reporting of clinical genetics testing for a variety of genetic disease areas with a focus on hearing loss. Dr. Amr serves as co-chair of the ClinGen Hearing Loss Working Group whose efforts focus on the standardization of variant classification and the assessment of gene-disease association in this disease area. He has also been involved in national committees to assess genetic screening as part of newborn hearing screen testing and on several clinical translational projects involving hearing loss testing.
Dr. Amr has authored or co-authored over 40 publications on clinical and technical aspects of genetic testing, molecular diagnostics, and approaches to genetic data interpretation. He has also lectured on a broad range of topics in the clinical diagnostics and biomarkers discoveries at national and international conferences. In addition, Dr. Amr plays an active role in the mentorship and training of clinical and laboratory AMBGG fellows as well genetic counselors, medical students, and colleagues
Associate Director, MGB Laboratory of Molecular Medicine
Director, Translational Genomics Core, MGB Personalized Medicine
Assistant Professor of Pathology Harvard Medical School
Dr. Sami S Amr is an Assistant Professor in the
Department of Pathology at Brigham and Women’s Hospital and Harvard Medical
School. He is also Associate Director of the Laboratory of Molecular Medicine
and Director of the Biobank Genomics Core at Mass General Brigham Personalized
Medicine. Dr. Amr is also board certified in clinical molecular genetics by the
American Board of Medical Genetics and Genomics (ABMGG).
Dr. Amr’s career spans over 10 years in clinical molecular diagnostics, where he has led the development and implementation of several clinical assays including large gene panels for inherited disease as well as smaller panels/assays for technically challenging regions or genes. In addition, has been involved in analysis, interpretation and reporting of clinical genetics testing for a variety of genetic disease areas with a focus on hearing loss. Dr. Amr serves as co-chair of the ClinGen Hearing Loss Working Group whose efforts focus on the standardization of variant classification and the assessment of gene-disease association in this disease area. He has also been involved in national committees to assess genetic screening as part of newborn hearing screen testing and on several clinical translational projects involving hearing loss testing.
Dr. Amr has authored or co-authored over 40 publications on clinical and technical aspects of genetic testing, molecular diagnostics, and approaches to genetic data interpretation. He has also lectured on a broad range of topics in the clinical diagnostics and biomarkers discoveries at national and international conferences. In addition, Dr. Amr plays an active role in the mentorship and training of clinical and laboratory AMBGG fellows as well genetic counselors, medical students, and colleagues
Journal article
In recent years, there has been increased focus on exploring the role the non-protein-coding genome plays in Mendelian disorders. One class of particular interest is long non-coding RNAs (lncRNAs), which has recently been implicated in the regulation of diverse molecular processes. However, because lncRNAs do not encode protein, there is uncertainty regarding what constitutes a pathogenic lncRNA variant, and thus annotating such elements is challenging. The Developmental Genome Anatomy Project...
Journal article
CONCLUSIONS AND RELEVANCE: In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.
